Interleukin-6 inhibitors in the treatment of rheumatoid arthritis

References

• AndrewsNC2004Anemia of inflammation: the cytokine-hepcidin linkJ Clin Invest11391271615124018
   PubMed Web of Science ®Google Scholar
• ChoyEHSIsenbergDAGarroodT2002Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trialArthritis Rheum4631435012483717
   PubMed Web of Science ®Google Scholar
• CronsteinBN2007Interleukin-6: A key mediator of systemic and local symptoms in rheumatoid arthritisBull NYU Hosp Jt Dis65Suppl 1S111517708739
   PubMedGoogle Scholar
• GartlehnerGHansenRAJonasBL2006The comparative Efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysisJ Rheumatol33239840817225293
   PubMed Web of Science ®Google Scholar
• GenoveseMMcKayJNasonovE2007IL-6 receptor inhibition with Tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD studyACR/ARHP Scientific Meeting 2007Presentation L15.
   Google Scholar
• Gomez-ReinoJJFairfaxMJPavelkaK2007Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDsACR/ARHP Scientific Meeting 2007Poster 522.
   Google Scholar
• HeinrichPCBehrmannIHaanS2003Principles of interleukin (IL)-6-type cytokine signaling and its regulationBiochem J37412012773095
   PubMed Web of Science ®Google Scholar
• IshibashiTShikamaYKimuraH1993Thrombopoietic effects of inter-leukin-6 in long-term administration in miceExp Hematol2164068513864
   PubMed Web of Science ®Google Scholar
• ItoH2005Treatment of Crohn’s disease with anti-IL-6 receptor antibodyJ Gastroenterol40Suppl 1632415902961
   PubMed Web of Science ®Google Scholar
• KavanaughACohenSCushJ2004The evolving use of TNF inhibitors in rheumatoid arthritisJ Rheumatol311881415468347
   PubMed Web of Science ®Google Scholar
• KudoOSabokbarAPocockA2003nterleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanismBone321712584029
   PubMed Web of Science ®Google Scholar
• LipskyPE2006Interleukin-6 and rheumatic diseasesArthritis Res Ther8Suppl 2S416899108
   PubMed Web of Science ®Google Scholar
• MadhokRCrillyAMurphyE1993bGold therapy lowers serum interleukin 6 levels in rheumatoid arthritisJ Rheumatol2063038496855
   PubMed Web of Science ®Google Scholar
• MadhokRCrillyAWatsonJ1993aSerum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activityAnn Rheum Dis52232588484679
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJ2006Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum5428172916947782
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaN2007bStudy of active controlled monotherapy used for rheumatoid arthritis, and IL-6 inhibitor (SAMURAI): -Evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumabAnn Rheum Dis661162717485422
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoK2007aLong-term safety and Efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy in patients with rheumatoid arthritisAnn Rheum Dis66Suppl IIOP0227
   Google Scholar
• NishimotoNSasaiMShimaY2000Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapyBlood95566110607684
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMaedaK2003Toxicity, pharmacokinetics and dose finding study of repetitive treatment with the humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritisJ Rheumatol3014263512858437
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaN2004Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trialArthritis Rheum501761915188351
   PubMed Web of Science ®Google Scholar
• OhsugiYKishimotoT2008The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritisExpert Opin Biol Ther86698118407769
   PubMed Web of Science ®Google Scholar
• ParkJYPillingerMH2007Interleukin-6 in the pathogenesis of rheumatoid arthritisBull NYU Hosp Jt Dis65Suppl 1S41017708744
   PubMedGoogle Scholar
• PrevooMLvan GestelAMvan T HofMA1996Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity scoreBr J Rheumatol35110158948296
   PubMedGoogle Scholar
• Rose-JohnSWaetzigGHSchellerJ2007The IL-6/IL-6R complex as a novel target for therapeutic approachesExpert Opin Ther Targets1161362417465721
   PubMed Web of Science ®Google Scholar
• Rose-JohnS2003Interleukin-6 biology is coordinated by membrane bound and soluble receptorsActa Biochim Pol506031114515143
   PubMed Web of Science ®Google Scholar
• SerioloBPaolinoSSulliA2006Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritisAnn N Y Acad Sci1069414916855168
   PubMed Web of Science ®Google Scholar
• SmolenJBeaulieuARubbert-RothA2008Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet37196179879718358926
   PubMed Web of Science ®Google Scholar
• StraubRHMuller-LadnerULichtingerT1997Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugsBr J Rheumatol3612983039448591
   PubMedGoogle Scholar
• YokotaSImagawaTMoriM2008Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trialLancet3719617998100618358927
   PubMed Web of Science ®Google Scholar
• YoshizakiKNishimotoNMiharaM1998Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with humanized anti-IL-6 receptor antibodySpringer Seminar Immunopathol2024759
   PubMed Web of Science ®Google Scholar